
S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Next‑gen PARP agents and tolerability
Heather McArthur describes PETRA first‑in‑human data and a PARP1‑selective agent with improved GI tolerability.
Play episode from 02:23
Transcript


